Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer.
Leonardo Roberto da SilvaCamila Annicchino de AndradeFabrício BrenelliSusana RamalhoTomás ReinertAlessandra Borba Anton de SouzaAna Elisa Ribeiro da SilvaMaria Beatriz de Paula Leite KraftVivian Castro Antunes de VasconcelosAntônio Luiz FrassonRenato Zochio TorresanCesar CabelloMatthew J EllisLuiz Carlos ZeferinoPublished in: Breast cancer research and treatment (2021)
Our real-world data shows that NET is effective and safe in postmenopausal patients with ER-positive/HER2-negative breast cancer. Postmenopausal status and low-risk luminal tumor features (luminal A-like) should be used as selection criteria to ensure the best results with NET.